The earnings call presented a mix of positive advancements in clinical markets and strategic acquisitions, alongside challenges in revenue decline and regulatory constraints in China. Significant emphasis on new product adoption and raised guidance indicates a positive outlook, despite some ongoing market challenges.

Company Guidance -

Q3 2025

During the Illumina Second Quarter 2025 Earnings Conference Call, the company provided guidance updates reflecting strong execution and operating discipline. Illumina reported Q2 revenue at the high end of guidance at approximately $1.06 billion, despite a year-over-year decline. Non-GAAP operating margin was 23.8%, with non-GAAP EPS at $1.19, exceeding expectations. The company raised full-year guidance for total revenue growth, non-GAAP operating margin, and non-GAAP EPS, now expecting revenues between $4.23 billion to $4.31 billion and a non-GAAP EPS range of $4.45 to $4.55. This revision was driven by strength in high-throughput consumables, particularly among NovaSeq X users, and resilience in clinical markets, which accounted for roughly 60% of sequencing consumables. The company also highlighted ongoing macroeconomic challenges, such as NIH funding uncertainty in the U.S. research market and export restrictions to China, while focusing on disciplined execution to achieve long-term financial targets, including expanding non-GAAP operating margins to 26% by 2027.

High-End Revenue Achievement and Profitability

Despite a year-over-year decline, Illumina delivered revenue at the high end of the guidance range at approximately $1.06 billion. Non-GAAP operating margin was 23.8% and a non-GAAP EPS of $1.19, reflecting profitability above expectations.

NovaSeq X Platform Adoption

Ongoing adoption of the NovaSeq X platform with greater than 50 placements and increased high-throughput consumable sales, especially among NovaSeq X users, were highlighted as key achievements.

Strength in Clinical Markets

Clinical markets now account for roughly 60% of total sequencing consumables, showing resilience and in some areas exceeding expectations. This includes growth in oncology, genetic disease testing, and reproductive health.

SomaLogic Acquisition

The announced acquisition of SomaLogic aims to expand Illumina's presence in affinity-based proteomics, delivering deep, actionable insights for drug discovery, diagnostics, and health monitoring.

MiSeq i100 Plus Success

Since its launch, more than 500 MiSeq i100 Plus instruments have been placed with positive customer feedback, highlighting faster turnaround times and ease of use.

Raised Guidance for 2025

Illumina raised its guidance for total company revenue growth as well as total reported revenue, non-GAAP operating margin, and non-GAAP EPS, reflecting strong execution and operating discipline.

Illumina (ILMN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ILMN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	1.17 / -	1.14	―	―	―
Jul 31, 2025	2025 (Q2)	1.01 / 1.19	0.36	230.56% (+0.83)
May 08, 2025	2025 (Q1)	0.94 / 0.97	0.087	1014.94% (+0.88)
Feb 06, 2025	2024 (Q4)	0.91 / 0.95	0.136	598.53% (+0.81)
Nov 04, 2024	2024 (Q3)	0.88 / 1.14	0.321	255.14% (+0.82)
Aug 06, 2024	2024 (Q2)	0.11 / 0.36	0.311	15.76% (+0.05)
May 02, 2024	2024 (Q1)	0.04 / 0.09	0.078	11.54% (<+0.01)
Feb 08, 2024	2023 (Q4)	0.02 / 0.14	0.136	0.00% (0.00)
Nov 09, 2023	2023 (Q3)	0.14 / 0.32	0.33	-2.73% (>-0.01)
Aug 09, 2023	2023 (Q2)	0.02 / 0.31	0.554	-43.86% (-0.24)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ILMN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$102.71	$94.66	-7.84%
May 08, 2025	$79.58	$75.76	-4.80%
Feb 06, 2025	$122.80	$111.06	-9.56%
Nov 04, 2024	$153.49	$154.96	+0.96%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.